GSK Seeks EMA Approval for Bepirovirsen in Chronic Hepatitis B Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy GSK?
Source: NASDAQ.COM
- Regulatory Submission Accepted: GSK plc announced that the European Medicines Agency has accepted its marketing authorization application for bepirovirsen, an antiviral drug for adults with chronic hepatitis B, marking a significant milestone in the company's drug development efforts.
- Clinical Trial Results: The application is based on positive outcomes from the B-Well 1 and B-Well 2 Phase III trials, indicating the drug's potential efficacy and safety in treating chronic hepatitis B, which could address a significant unmet medical need.
- Collaborative Development: GSK licensed bepirovirsen from Ionis Pharmaceuticals and collaborated on its development, showcasing the company's strategic partnerships in advancing innovative therapeutics.
- Market Potential Assessment: Although the drug is not yet approved anywhere globally, successful market entry could open new opportunities for GSK in the chronic hepatitis B treatment space, enhancing its competitive position in the biopharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GSK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GSK
Wall Street analysts forecast GSK stock price to fall
6 Analyst Rating
1 Buy
2 Hold
3 Sell
Moderate Sell
Current: 54.700
Low
20.15
Averages
38.72
High
55.60
Current: 54.700
Low
20.15
Averages
38.72
High
55.60
About GSK
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. General medicines include inhaled medicines for asthma and COPD with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The Company also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. It is in phase IIb clinical development for prophylactic protection against food allergens.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Clover Biopharmaceuticals Reports Phase I Trial Results for RSV Vaccine
- Clinical Trial Results: Clover Biopharmaceuticals' Phase I trial of its RSV PreF vaccine (SCB-1019) in the U.S. indicates that heterologous re-vaccination induces approximately 60-80% higher RSV neutralizing antibody levels compared to GSK's AREXVY, demonstrating significant efficacy in older adults.
- Antibody Level Restoration: The updated analysis reveals that SCB-1019 restores antibody levels to about 120-135% of the peak observed after the initial AREXVY dose, while AREXVY re-vaccination only restores approximately 75%, highlighting SCB-1019's superior immune response enhancement.
- Vaccine Coverage Potential: With over 40% of U.S. adults aged 60 and older having received a protein-based RSV vaccine, Clover's findings underscore the potential of its RSV+hMPV±PIV3 combination vaccine candidates to restore waning RSV protection and broaden coverage against related respiratory viruses.
- Ongoing Trial Progress: Clover's ongoing Phase II trial for these combination vaccines began enrollment in January 2026 and is still underway, reflecting the company's continued investment and strategic positioning in the respiratory virus vaccine development space.
See More
GSK Seeks EMA Approval for Bepirovirsen in Chronic Hepatitis B Treatment
- Regulatory Submission Accepted: GSK plc announced that the European Medicines Agency has accepted its marketing authorization application for bepirovirsen, an antiviral drug for adults with chronic hepatitis B, marking a significant milestone in the company's drug development efforts.
- Clinical Trial Results: The application is based on positive outcomes from the B-Well 1 and B-Well 2 Phase III trials, indicating the drug's potential efficacy and safety in treating chronic hepatitis B, which could address a significant unmet medical need.
- Collaborative Development: GSK licensed bepirovirsen from Ionis Pharmaceuticals and collaborated on its development, showcasing the company's strategic partnerships in advancing innovative therapeutics.
- Market Potential Assessment: Although the drug is not yet approved anywhere globally, successful market entry could open new opportunities for GSK in the chronic hepatitis B treatment space, enhancing its competitive position in the biopharmaceutical industry.
See More
Pfizer Seeks Approval for Lyme Disease Vaccine Despite Trial Setback
- Vaccine Development Update: Pfizer announced it will seek regulatory approval for its Lyme disease vaccine despite failing to meet statistical goals in late-stage trials; however, the vaccine demonstrated over a 70% reduction in infection rates, indicating its potential protective capability.
- Market Outlook Assessment: While Pfizer's partner Valneva estimates peak annual sales of $1 billion for the vaccine, Pfizer anticipates overall revenue of around $60 billion, with more than $5 billion coming from its COVID-19 vaccine, highlighting the competitive landscape in the vaccine market.
- Clinical Trial Challenges: In 2023, Pfizer and Valneva dropped about half of the participants due to quality concerns with a third-party clinical trial operator, reducing the trial size from approximately 18,000 to 9,400, which may impact the final efficacy assessment of the vaccine.
- Vaccine Policy Risks: Advancing a vaccine that technically failed a clinical trial under a stricter regulatory environment may pose risks for Pfizer and could serve as a litmus test for vaccine policy in the U.S.
See More
Pfizer Seeks Regulatory Approval for Lyme Disease Vaccine
- Vaccine Development Progress: Pfizer plans to seek regulatory approval for its Lyme disease vaccine despite failing to meet statistical goals in late-stage trials; however, the company claims the vaccine reduced infection rates by over 70% among recipients, indicating strong efficacy.
- Market Potential Assessment: Pfizer's partner Valneva estimates that the vaccine could achieve peak annual sales exceeding $1 billion, although Pfizer's overall revenue is projected at around $60 billion, with more than $5 billion coming from its Covid-19 vaccine, suggesting limited market prospects for the Lyme vaccine.
- Clinical Trial Challenges: In 2023, Pfizer and Valneva dropped about half of the participants in their Phase 3 trial due to quality concerns with a third-party clinical trial site operator, reducing enrollment from 18,000 to approximately 9,400, highlighting uncertainties in the vaccine development process.
- Vaccine Policy Risks: Advancing a vaccine that technically failed a clinical trial under an administration advocating stricter scrutiny may pose risks for Pfizer, potentially serving as a litmus test for vaccine policy in the U.S. and influencing future approvals and market acceptance.
See More
REGENXBIO INC ANNOUNCES SETTLEMENT AND RELEASE AGREEMENT WITH GLAXOSMITHKLINE DATED MARCH 18, 2026 - SEC FILING
Regeneron Bio Agreement: Regeneron has entered into a settlement and release agreement with GlaxoSmithKline regarding a legal matter.
Date of Agreement: The agreement was finalized on March 18, 2026, indicating a future-oriented resolution.
See More
GSK's Lynavoy Receives FDA Approval for Cholestatic Pruritus
- FDA Approval: GSK announced that its drug Lynavoy has received FDA approval for treating cholestatic pruritus associated with primary biliary cholangitis (PBC), marking the first approved treatment for this condition in the U.S., which is expected to significantly enhance patient quality of life.
- Successful Clinical Trials: The approval is supported by data from the GLISTEN Phase 3 trial, which demonstrated that Lynavoy led to a sustained reduction in cholestatic pruritus and itch-related sleep disturbances over 24 weeks, confirming its efficacy and safety in treatment.
- Global Collaboration Agreement: GSK has signed an agreement with Italian pharma company Alfasigma to manufacture and market Lynavoy globally, which will help accelerate the drug's market introduction and expand its market reach.
- Commitment to R&D: GSK's R&D head, Kaivan Khavandi, stated that Lynavoy is the first liver medicine from their pipeline to receive approval, underscoring the company's ongoing commitment to innovation in liver disease, with potential for further drug development in this area.
See More
Clover Biopharmaceuticals Reports Phase I Trial Results for RSV Vaccine
- Clinical Trial Results: Clover Biopharmaceuticals' Phase I trial of its RSV PreF vaccine (SCB-1019) in the U.S. indicates that heterologous re-vaccination induces approximately 60-80% higher RSV neutralizing antibody levels compared to GSK's AREXVY, demonstrating significant efficacy in older adults.
- Antibody Level Restoration: The updated analysis reveals that SCB-1019 restores antibody levels to about 120-135% of the peak observed after the initial AREXVY dose, while AREXVY re-vaccination only restores approximately 75%, highlighting SCB-1019's superior immune response enhancement.
- Vaccine Coverage Potential: With over 40% of U.S. adults aged 60 and older having received a protein-based RSV vaccine, Clover's findings underscore the potential of its RSV+hMPV±PIV3 combination vaccine candidates to restore waning RSV protection and broaden coverage against related respiratory viruses.
- Ongoing Trial Progress: Clover's ongoing Phase II trial for these combination vaccines began enrollment in January 2026 and is still underway, reflecting the company's continued investment and strategic positioning in the respiratory virus vaccine development space.
See More
GSK Seeks EMA Approval for Bepirovirsen in Chronic Hepatitis B Treatment
- Regulatory Submission Accepted: GSK plc announced that the European Medicines Agency has accepted its marketing authorization application for bepirovirsen, an antiviral drug for adults with chronic hepatitis B, marking a significant milestone in the company's drug development efforts.
- Clinical Trial Results: The application is based on positive outcomes from the B-Well 1 and B-Well 2 Phase III trials, indicating the drug's potential efficacy and safety in treating chronic hepatitis B, which could address a significant unmet medical need.
- Collaborative Development: GSK licensed bepirovirsen from Ionis Pharmaceuticals and collaborated on its development, showcasing the company's strategic partnerships in advancing innovative therapeutics.
- Market Potential Assessment: Although the drug is not yet approved anywhere globally, successful market entry could open new opportunities for GSK in the chronic hepatitis B treatment space, enhancing its competitive position in the biopharmaceutical industry.
See More
Pfizer Seeks Approval for Lyme Disease Vaccine Despite Trial Setback
- Vaccine Development Update: Pfizer announced it will seek regulatory approval for its Lyme disease vaccine despite failing to meet statistical goals in late-stage trials; however, the vaccine demonstrated over a 70% reduction in infection rates, indicating its potential protective capability.
- Market Outlook Assessment: While Pfizer's partner Valneva estimates peak annual sales of $1 billion for the vaccine, Pfizer anticipates overall revenue of around $60 billion, with more than $5 billion coming from its COVID-19 vaccine, highlighting the competitive landscape in the vaccine market.
- Clinical Trial Challenges: In 2023, Pfizer and Valneva dropped about half of the participants due to quality concerns with a third-party clinical trial operator, reducing the trial size from approximately 18,000 to 9,400, which may impact the final efficacy assessment of the vaccine.
- Vaccine Policy Risks: Advancing a vaccine that technically failed a clinical trial under a stricter regulatory environment may pose risks for Pfizer and could serve as a litmus test for vaccine policy in the U.S.
See More
Pfizer Seeks Regulatory Approval for Lyme Disease Vaccine
- Vaccine Development Progress: Pfizer plans to seek regulatory approval for its Lyme disease vaccine despite failing to meet statistical goals in late-stage trials; however, the company claims the vaccine reduced infection rates by over 70% among recipients, indicating strong efficacy.
- Market Potential Assessment: Pfizer's partner Valneva estimates that the vaccine could achieve peak annual sales exceeding $1 billion, although Pfizer's overall revenue is projected at around $60 billion, with more than $5 billion coming from its Covid-19 vaccine, suggesting limited market prospects for the Lyme vaccine.
- Clinical Trial Challenges: In 2023, Pfizer and Valneva dropped about half of the participants in their Phase 3 trial due to quality concerns with a third-party clinical trial site operator, reducing enrollment from 18,000 to approximately 9,400, highlighting uncertainties in the vaccine development process.
- Vaccine Policy Risks: Advancing a vaccine that technically failed a clinical trial under an administration advocating stricter scrutiny may pose risks for Pfizer, potentially serving as a litmus test for vaccine policy in the U.S. and influencing future approvals and market acceptance.
See More
REGENXBIO INC ANNOUNCES SETTLEMENT AND RELEASE AGREEMENT WITH GLAXOSMITHKLINE DATED MARCH 18, 2026 - SEC FILING
Regeneron Bio Agreement: Regeneron has entered into a settlement and release agreement with GlaxoSmithKline regarding a legal matter.
Date of Agreement: The agreement was finalized on March 18, 2026, indicating a future-oriented resolution.
See More
GSK's Lynavoy Receives FDA Approval for Cholestatic Pruritus
- FDA Approval: GSK announced that its drug Lynavoy has received FDA approval for treating cholestatic pruritus associated with primary biliary cholangitis (PBC), marking the first approved treatment for this condition in the U.S., which is expected to significantly enhance patient quality of life.
- Successful Clinical Trials: The approval is supported by data from the GLISTEN Phase 3 trial, which demonstrated that Lynavoy led to a sustained reduction in cholestatic pruritus and itch-related sleep disturbances over 24 weeks, confirming its efficacy and safety in treatment.
- Global Collaboration Agreement: GSK has signed an agreement with Italian pharma company Alfasigma to manufacture and market Lynavoy globally, which will help accelerate the drug's market introduction and expand its market reach.
- Commitment to R&D: GSK's R&D head, Kaivan Khavandi, stated that Lynavoy is the first liver medicine from their pipeline to receive approval, underscoring the company's ongoing commitment to innovation in liver disease, with potential for further drug development in this area.
See More
